Climbing up from the cliff: PhRMA argues R&D pipeline vibrant, diverse
This article was originally published in Scrip
Executive Summary
For those who have asserted that the patent cliff has the biopharmaceutical industry stuck in its tracks, representatives of the sector on 17 January used a new analysis to argue the R&D pipeline for new medicines is "vibrant and diverse."